Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
@article{160988, author = {Suneel Sharma and M. L. Agarwal}, title = {Profitability, leverageand ratio analysis of top seven pharmaceutical companies}, journal = {International Journal of Innovative Research in Technology}, year = {}, volume = {10}, number = {2}, pages = {257-261}, issn = {2349-6002}, url = {https://ijirt.org/article?manuscript=160988}, abstract = {The study provides an in-depth analysis of all the companies’ financial position thereby reflecting the concerned industry’s financial position which enables the existing and potential investors and creditors to take investment and lending decisions.The study focuses on the management's ability to manage profitability, growth of company and financial leverage.It can provide a decision making frame work for the government to determine any policy for the benefit of specific industry or industries which has/have been examined.Financial performance was measured as Return on Equity.The study investigated several variables viz. DER, Debt to total assets ratio, ICR, ROA ratio and ROE ratio. This study uses regression technique for the analysis of the data. The study has analysed a sampleof 7 pharmaceutical companies for a period of 10 years from 2012-2013 to 2021-2022.The data analysis reveals that considerable differences are found in Return on Equity between the selected Indian pharmaceutical industries.}, keywords = {Leverage, pharmaceutical companies, accounting, shareholder, debt, ROE}, month = {}, }
Cite This Article
Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.
Join NowNational Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024
Submit inquiry